Updates are available Correction dated 2021-03-02
Click to view Correction: https://doi.org/10.1038/s41589-021-00767-w
-
Authors
Zou, Yilong
Li, Haoxin
Graham, Emily T. https://orcid.org/0000-0001-6696-4564
Deik, Amy A.
Eaton, John K. https://orcid.org/0000-0003-4633-5546
Wang, Wenyu
Sandoval-Gomez, Gerardo
Clish, Clary B. https://orcid.org/0000-0001-8259-9245
Doench, John G. https://orcid.org/0000-0002-3707-9889
Schreiber, Stuart L. https://orcid.org/0000-0003-1922-7558
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA217848)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM127045)
- License Information
-
More Information
Article History
Received: 21 February 2019
Accepted: 8 January 2020
First Online: 17 February 2020
Change Date: 2 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-021-00767-w
Competing interests
: S.L.S. serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (GNF); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Decibel Therapeutics and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics, and F-Prime Capital Partners; and is a Novartis Faculty Scholar. The remaining authors declare no competing interests.
